SUMMARY
# Mixed Pathology Effects on Parkinson's Disease Progression and Treatment Response
## Background and Rationale
This clinical study investigates the impact of mixed pathology—specifically concurrent Alzheimer's disease (AD) and Parkinson's disease (PD) pathology—on disease progression and treatment response in patients with parkinsonism. Growing evidence suggests that up to 50% of PD patients develop AD-related pathology, including amyloid plaques and tau tangles, which may accelerate cognitive
METHODOLOGY NOTES
Phase 1 (Months 0-3): Recruit 450 participants across three cohorts (150 each): pure PD, pure AD, and mixed pathology patients. Conduct comprehensive baseline assessments including neurological examinations, cognitive testing (MoCA, MMSE), motor evaluations (UPDRS-III), and quality of life measures. Obtain CSF samples for biomarker analysis and perform baseline neuroimaging (18F-flutemetamol PET, DaTscan, structural MRI). Phase 2 (Months 3-24): Implement standardized treatment protocols—levodopa/carbidopa for PD symptoms, cholinesterase inhibitors for cognitive symptoms. Conduct quarterly follow-up assessments measuring cognitive decline rates, motor symptom progression, and treatment response. Monitor adverse events and medication adherence. Phase 3 (Months 24-36): Continue longitudinal tracking with biannual assessments. Perform repeat neuroimaging at 18 and 36 months. Collect additional CSF samples at 12-month intervals. Analyze treatment response patterns, progression rates, and bi